<DOC>
	<DOCNO>NCT02431429</DOCNO>
	<brief_summary>This study Phase 4 , open-label , single group study least 55 evaluable adult male patient undergoing miltefosine treatment mucocutaneous leishmaniasis provide semen sample spermiogram analysis sperm parameter .</brief_summary>
	<brief_title>Spermiogram Assessment Bolivian Patients Taking ImpavidoÂ® ( Miltefosine ) Mucocutaneous Leishmaniasis</brief_title>
	<detailed_description>This study Phase 4 , open-label , single group study least 55 evaluable adult male patient undergoing miltefosine treatment mucocutaneous leishmaniasis provide semen sample spermiogram analysis sperm parameter . Potential subject diagnose mucocutaneous leishmaniasis planning undergo miltefosine treatment inform study undergo inform consent process . After obtain informed consent , subject screen 28-day period eligibility medical history include leishmaniasis diagnostics , physical examination , clinical laboratory measurement [ chemistry : ( ALT , total bilirubin , creatinine ; hematology : WBC count , hemoglobin , platelet count ; spermiogram : sperm concentration , total sperm count , semen volume , sperm motility , sperm morphology ; hormone : testosterone FSH ] ; medication use 28-day period start treatment . If eligible study , subject receive miltefosine 28 day target dose approximately 2.5 mg/kg/day . Screening enrollment study continue least 55 subject complete study consider evaluable ( provide sperm sample per protocol complete least 25 28 day miltefosine treatment ) . Chemistries hematology repeat study Days 14 ( mid-treatment ) 28 ( end treatment ) . Two semen sample collect screen ( least 48 hour apart ) , end treatment ( Days 25-and-28 ) , 3-months completing treatment . If clinically significant change spermiogram finding observe 3 month , one sample collect 6 month . Adverse event ( AEs ) concomitant medication use collect treatment . Concomitant medication use also collect 3-month visit subject come back 6-month visit . A medical history take 3-month 6-month ( conduct ) focus change urogenital system .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>1 . Provide write informed consent . 2 . Be available complete study procedure 3 . Have diagnosis mucocutaneous leishmaniasis confirm microscopy stain smear lesion sample , culture lesion sample , polymerase chain reaction ( PCR ) lesion sample Montenegro skin test planning undergo treatment miltefosine 4 . Be male 1855 year age 5 . Have ALT , total bilirubin , creatinine &lt; 1.5 upper limit normal ( ULN ) 6 . Have value ion might affect ECG ( magnesium , calcium , potassium , sodium ) within normal laboratory limit ( WNL ) 7 . Have WBC count , hemoglobin , platelet count within 15 % normal laboratory limit ( WNL ) 8 . Have know history male sexual dysfunction 9 . Have vasectomy agree vasectomy duration study 10 . Have testosterone WNL ( &gt; 300 ng/dL ) FSH WNL ( 1.5 2.4 mIU/mL ) 11 . Have screen semen parameter ( mean test ) : 1. semen volume least 1.5 mL 2. total sperm count great 45 million 3. sperm concentration great 30 million/mL 4. sperm motility great 50 % ( total percentage progressively motile sperm ) 5. normal sperm morphology strict criterion &gt; 10 % 1 . Have presence psychological physiological abnormality opinion Investigator would significantly impair sexual performance ability provide semen sample accord protocol 2 . Have evidence history psychotropic central nervous system drug ( e.g. , antidepressant , antiepileptic ) , antihypertensives , calcium channel blocker , chemotherapy drug , colchicine , therapeutic hormone , finasteride , sulfasalazine , use nicotine containing product urine toxicology test marijuana ( tetrahydrocannabinol ) cocaine . 3 . Have history surgical prostatectomy 4 . Have positive serology Chagas Disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>spermiogram</keyword>
</DOC>